Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
16 déc. 2024 10h53 HE
|
Research and Markets
Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028" report has been added to ...
Peptide Cancer Drug Market Research 2024-2030: 230 Drugs in Clinical Trials, 30 Approved Drugs, $18 Billion Opportunity, Commercially Approved Peptide Cancer By Brand Name, Company and Indication
27 nov. 2024 04h10 HE
|
Research and Markets
Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The "Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...
Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight
25 nov. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming...
Neuroendocrine Tumors (NETs) Market Research 2024-2030 with Analyst Recommendations - Establishment of Specialist Therapeutic Centers / Organize Campaigns to Raise Awareness
01 oct. 2024 06h48 HE
|
Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of...
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
09 sept. 2024 04h56 HE
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User,...
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
09 juil. 2024 09h47 HE
|
Curium
Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
16 oct. 2023 05h30 HE
|
Research Nester
New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
03 oct. 2023 07h00 HE
|
Research Nester
New York, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is predicted to expand at ~ 6% CAGR between 2023 and 2035. The market is projected to garner a revenue of USD...
Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
29 mai 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
06 sept. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...